Affiliations

• ¹ From the Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (K.A.); Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan (K.A.); Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluations, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China (Y.L.); Heart Disease Prevention Program, Division of Cardiology, School of Medicine, University of California-Irvine (S.S.F.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (L.T., J.A.S.); Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Ireland (E.O.); and R&D Group VitaK, Maastricht University, The Netherlands (J.A.S.).
• ² From the Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan (K.A.); Department of Planning for Drug Development and Clinical Evaluation, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan (K.A.); Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluations, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China (Y.L.); Heart Disease Prevention Program, Division of Cardiology, School of Medicine, University of California-Irvine (S.S.F.); Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Belgium (L.T., J.A.S.); Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Ireland (E.O.); and R&D Group VitaK, Maastricht University, The Netherlands (J.A.S.). jan.staessen@med.kuleuven.be ja.staessen@maastrichtuniversity.nl.